Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Jonathan Zheng Li, M.D.

Co-Author

This page shows the publications co-authored by Jonathan Li and Rajesh Gandhi.
Connection Strength

3.963
  1. The Search for an HIV Cure: Where Do We Go From Here? J Infect Dis. 2021 02 15; 223(12 Suppl 2):1-3.
    View in: PubMed
    Score: 0.961
  2. The size of the expressed HIV reservoir predicts timing of viral rebound after treatment interruption. AIDS. 2016 Jan 28; 30(3):343-53.
    View in: PubMed
    Score: 0.677
  3. The sooner, the better: more evidence that early antiretroviral therapy lowers viral reservoirs in HIV-infected infants. J Infect Dis. 2014 Nov 15; 210(10):1519-22.
    View in: PubMed
    Score: 0.602
  4. Time to Viral Rebound After Interruption of Modern Antiretroviral Therapies. Clin Infect Dis. 2021 Jun 12.
    View in: PubMed
    Score: 0.246
  5. The Control of HIV After Antiretroviral Medication Pause (CHAMP) Study: Posttreatment Controllers Identified From 14 Clinical Studies. J Infect Dis. 2018 11 05; 218(12):1954-1963.
    View in: PubMed
    Score: 0.205
  6. HIV-1 proviral landscapes distinguish posttreatment controllers from noncontrollers. J Clin Invest. 2018 08 31; 128(9):4074-4085.
    View in: PubMed
    Score: 0.202
  7. Effect of Short-Term Antiretroviral Therapy Interruption on Levels of Integrated HIV DNA. J Virol. 2018 06 15; 92(12).
    View in: PubMed
    Score: 0.199
  8. Impact of HLA Class I Alleles on Timing of HIV Rebound After Antiretroviral Treatment Interruption. Pathog Immun. 2017; 2(3):431-445.
    View in: PubMed
    Score: 0.192
  9. Brief Report: Relationship Among Viral Load Outcomes in HIV Treatment Interruption Trials. . 2016 07 01; 72(3):310-3.
    View in: PubMed
    Score: 0.174
  10. Origin of Rebound Plasma HIV Includes Cells with Identical Proviruses That Are Transcriptionally Active before Stopping of Antiretroviral Therapy. J Virol. 2016 02 01; 90(3):1369-76.
    View in: PubMed
    Score: 0.167
  11. Developing Treatment Guidelines During a Pandemic Health Crisis: Lessons Learned From COVID-19. Ann Intern Med. 2021 08; 174(8):1151-1158.
    View in: PubMed
    Score: 0.061
  12. Frequency of Post Treatment Control Varies by ART Restart and Viral Load Criteria. AIDS. 2021 Jun 14.
    View in: PubMed
    Score: 0.061
  13. Participant Perspectives and Experiences Entering an Intensively Monitored Antiretroviral Pause: Results from the AIDS Clinical Trials Group A5345 Biomarker Study. AIDS Res Hum Retroviruses. 2021 06; 37(6):489-501.
    View in: PubMed
    Score: 0.060
  14. Time to viral rebound and safety after antiretroviral treatment interruption in postpartum women compared with men. AIDS. 2019 11 15; 33(14):2149-2156.
    View in: PubMed
    Score: 0.055
  15. Recommendations for analytical antiretroviral treatment interruptions in HIV research trials-report of a consensus meeting. Lancet HIV. 2019 04; 6(4):e259-e268.
    View in: PubMed
    Score: 0.053
  16. Human Immunodeficiency Virus Type 1 Persistence Following Systemic Chemotherapy for Malignancy. J Infect Dis. 2017 07 15; 216(2):254-262.
    View in: PubMed
    Score: 0.047
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.